抗癌纳米药物共递送系统的应用研究

Abstract
Figure/Table
References
Related Citation (15)

Download:

Full Text ( PDF ) (3667KB)
Export: BibTeX | EndNote (RIS)

Abstract In recent years,the application of targeted nanotechnology has achieved good therapeutic effects in cancer treatment, especially the co-delivery of various anti-cancer drugs. Compared with single drug treatment, the combined application of different molecular targeted drugs has a wider treatment domain and effectively reduce adverse effects of drugs. In addition, the combination therapy of anti-cancer agents dependent on the same cell pathway decrease the dosage of each drug and enhance therapeutic effects. The aforementioned methods could reverse multi-drug resistance to a certain extent. However, combined administration is limited due to inconsistent cellular uptake caused by pharmacokinetic differences of different drugs. The therapeutic effects are closely related to the relative concentration of the combined drugs. A certain proportion of drug combinations could produce synergistic effect, while other proportions may be additive effect or antagonistic effect. At present, the nanocarriers, including liposomes, polymer micelles, polymer vesicles, dendrimers, hydrogels and inorganic nanoparticles have been demonstrated to deliver anti-cancer agents in various tumor models. These nanocarriers could improve serum stability, enhance biocompatibility and prolong in vivo circulation time. In the present review, we will highlight the co-delivery principle of anti-cancer drugs, the types of co-delivery carriers, two kinds of liposomes on the CombiPlex^ platform whose clinical trials have been completed, and three kinds of classical co-delivery drug systems that are still in preclinical research, including doxorubicin and paclitaxel co-delivery systems, paclitaxel and cisplatin co-delivery systems, doxorubicin and curcumin co-delivery systems. These emerging strategies promise reference and novel ideas for more combinatorial regimens.

Key words： nanomedicine co-delivery anti-cancer agents multi-drug resistance

Published: 01 July 2020

CLC number:	TB324
	R73

Fund:This work was financially supported by the National Natural Science Foundation of China (21664007), the Cultivation Project for Academic and Technical Leaders of Major Disciplines of Jiangxi Province (20153BCB22009), and the Graduate Innovation Special Fund of Jiangxi Province (YC2019-S407).

About author:: Tianyi Wu graduated from Hebei Medical University with a major in pharmaceutical analysis in 2017. She served as an experimental technician in Hebei Saint Snow Tangshan Pharmaceutical Co., Ltd. for one year upon graduation. At present, she is a master's graduate student from School of Life Science, Jiangxi Science & ; Technology Normal University. She is performing research under the guidance of Prof. Xiangyuan Xiong. Her research interest focuses on polymer biomedical materials, such as the synthesis and characterization of folic acid targeted nano-particles, co-delivery anti-cancer drugs release systems, and related cytoto-xicity and drug uptake ; Xiangyuan Xiong obtained her M.E. degree in polymer chemistry and physics from Peking University in 2001. Subsequently, she pursued advanced studies in Nanyang Technological University (NTU) and received her Ph.D. degree in May 2005. She served as research associate of Singapore-MIT Alliance (SMA) in Aug. 2004—Mar. 2005. She is currently a professor at School of Jiangxi Science & ; Technology Normal University and an academic and technical leader of major disciplines of Jiangxi Province. She was selected for the candidate for the “One Million Talents Project of Jiangxi Province” in 2009 and an advanced worker of Nanchang City in 2010. She specializes in nano-scale polymer vehicles, including the controllable synthesis and characterization of biocompatible and biodegra-dable block copolymers, the aggregation morphology and particle size in water. In addition, she focuses on the application research of nanoparticles in biomedical field, especially the controlled release system and targeted release system. She has published more than 20 SCI papers in the Journal of Controlled Release, Nanomedicine and other well-known international journals. She acquired the second prize of “the Higher School Science and Technology Achievement Award of Jiangxi Province” in 2007—2008 and the third prize of “the Natural Science Award of Jiangxi Province” in 2009.

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Tianyi
	GONG Yanchun
	LI Ziling
	LI Yuping
	XIONG Xiangyuan

Cite this article:

WU Tianyi,GONG Yanchun,LI Ziling, et al. Application of Nanoparticle-based Co-delivery Strategies for Cancer Therapy[J]. Materials Reports, 2020, 34(Z1): 516-522.

URL:

http://www.mater-rep.com/EN/ OR http://www.mater-rep.com/EN/Y2020/V34/IZ1/516

1 Bray F, Ferlay J, Soerjomataram I, et al. CA: A Cancer Journal for Clinicians,2018,68(6),394.
2 El-Zahaby S A, Elnaggar Y S R, Abdallah O Y. Journal of Controlled Release,2019,293,21.
3 Barenholz Y C. Journal of Controlled Release,2012,160(2),117.
4 Keam B, Lee K W, Lee S H, et al. The Oncologist,2019,24,751.
5 Silverman J A, Deitcher S R. Cancer Chemotherapy and Pharmacology,2013,71(3),555.
6 Marusyk A, Almendro V, Polyak K. Nature Reviews Cancer,2012,12(5),323.
7 Greco F, Vicent M J. Advanced Drug Delivery Reviews,2009,61(13),1203.
8 Hartwell L H, Kastan M B. Science,1994,266(5192),1821.
9 Evan G I, Vousden K H. Nature,2001,411(6835),342.
10 Chen Y, Cheng Y, Zhao P, et al. International Journal of Pharmaceutics,2018,542(1-2),266.
11 Ruttala H B, Ramasamy T, Gupta B, et al. Carbohydrate Polymers,2017,173,57.
12 Chou T C. Cancer Research,2010,70(2),440.
13 Dicko A, Mayer L D, Tardi P G. Expert Opinion on Drug Delivery,2010,7(12),1329.
14 Mayer L D, Harasym T O, Tardi P G, et al. Molecular Cancer Therapeutics,2006,5(7),1854.
15 Abraham S A, Mckenzie C, Masin D, et al. Clinical Cancer Research,2004,10(2),728.
16 Shen Z, Ye H, Kroger M, et al. Nanoscale,2018,10(9),4545.
17 Katragadda U, Teng Q, Rayaprolu B M, et al. International Journal of Pharmaceutics,2011,419(1-2),281.
18 Palivan C G, Goers R, Najer A, et al. Chemical Society Reviews,2016,45(2),377.
19 Lin J, Cai Q, Tang Y, et al. International Journal of Pharmaceutics,2018,536(1),272.
20 Chen Y, Zhang W, Huang Y, et al. International Journal of Pharmaceutics,2015,488(1-2),44.
21 Jabr-Milane L S, Van Vlerken L E, Yadav S, et al. Cancer Treatment Reviews,2008,34(7),592.
22 Pan J Y, Rostamizadeh K, Filipczak N, et al. Molecules,2019,24(6),32.
23 Guo Q, Li X, Yang Y, et al. Journal of Biomedical Nanotechnology,2014,10(2),227.
24 Torchilin V. Advanced Drug Delivery Reviews,2011,63(3),131.
25 Danhier F, Feron O, Preat V. Journal of Controlled Release,2010,148(2),135.
26 Zhong Y, Meng F, Deng C, et al. Biomacromolecules,2014,15(6),1955.
27 Du J, Mao C, Yuan Y, et al. Biotechnology Advances,2014,32(4),789.
28 Abouelmagd S A, Hyun H, Yeo Y. Expert Opinion on Drug Delivery,2014,11(10),1601.
29 Hu C M J, Zhang L F. Biochemical Pharmacology,2012,83(8),1104.
30 Brandl M. Biotechnology Annual Review,2001,7,59.
31 Cheng Y, Zhao P, Wu S, et al. International Journal of Pharmaceutics,2018,545(1-2),261.
32 Kester M, Shanmugavelandy S S, Fox T. U.S. patent application, US8747891 B2,2014.
33 Fiallo M M, Garnier-Suillerot A, Matzanke B, et al. Journal of Inorganic Biochemistry,1999,75(2),105.
34 Taggar A S, Alnajim J, Anantha M, et al. Journal of Controlled Release,2006,114(1),78.
35 Yao Q, Gutierrez D C, Hoang N H, et al. Molecular Pharmaceutics,2017,14(7),2378.
36 Yang Z, Sun N, Cheng R, et al. Biomaterials,2017,147,53.
37 Nehate C, Moothedathu R A A, Haridas V, et al. Biomacromolecules,2018,19(7),2549.
38 Laskar P, Dey J, Ghosh S K. Journal of Colloid and Interface Science,2017,501,22.
39 Lin T, Fang Q, Peng D, et al. Drug Delivery,2013,20(7),277.
40 Yassin M A, Appelhans D, Wiedemuth R, et al. Small,2015,11(13),1580.
41 Pavot V, Berthet M, Resseguier J, et al. Nanomedicine,2014,9(17),2703.
42 Xiong X Y, Li Q H, Li Y P, et al. Colloids and Surfaces B-Biointerfaces,2013,111,282.
43 Liang Y, Peng X, Chen Y, et al. RSC Advances,2015,5(73),59014.
44 Wang H, Zhao Y, Wu Y, et al. Biomaterials,2011,32(32),8281.
45 Qin Y, Zhang Z, Huang C, et al. Journal of Biomedical Nanotechnology,2018,14(10),1705.
46 Chen K T J, Gilabert-Orial R, Bally M B, et al. Pharmaceutical Research,2019,36(9),125.
47 Tardi P G, Dos S N, Harasym T O, et al. Molecular Cancer Therapeutics,2009,8(8),2266.
48 Lancet J E, Uy G L, Cortes J E, et al. Journal of Clinical Oncology,2018,36(26),2684.
49 Wang Q, Banerjee K, Vasilinin G, et al. Journal of Clinical Pharmacology,2019,59(5),748.
50 Tardi P, Harasym T, Bermudes D, et al. Cancer Research,2009,69,1.
51 Parsels L A, Parsels J D, Tai D C H, et al. Cancer Research,2004,64(18),6588.
52 Batist G, Gelmon K A, Chi K N, et al. Clinical Cancer Research,2009,15(2),692.
53 Mackay J A, Chen M, Mcdaniel J R, et al. Nature Materials,2009,8(12),993.
54 Ma Y, Fan X, Li L. Carbohydrate Polymers,2016,137,19.
55 Yang M, Ding H, Zhu Y, et al. Colloids and Surfaces B-Biointerfaces,2019,175,126.
56 Wan X, Beaudoin J J, Vinod N, et al. Biomaterials,2019,192,1.
57 Liu B, Han L, Liu J, et al. International Journal of Nanomedicine,2017,12,955.
58 Zhang J, Li J, Shi Z, et al. Acta Biomaterialia,2017,58,349.
59 Karavasili C, Andreadis D A, Katsamenis O L, et al. Molecular Pharmaceutics,2019,16(6),2326.
60 Qu C Y, Zhou M, Chen Y W, et al. International Journal of Nanomedicine,2015,10,3911.
61 Duan W, Liu Y. Drug Design, Development and Therapy,2018,12,2149.
62 Tian J, Min Y, Rodgers Z, et al. Journal of Materials Chemistry B,2017,5(30),6049.
63 Yang J, Ju Z, Dong S. Drug Delivery,2017,24(1),792.
64 Zhang Y, Yang C, Wang W, et al. Scientific Reports,2016,6,21225.
65 Duan J, Mansour H M, Zhang Y, et al. International Journal of Pharmaceutics,2012,426(1-2),193.
66 Zhao X, Chen Q, Li Y, et al. European Journal of Pharmaceutics and Biopharmaceutics,2015,93,27.
67 Li Y, Liu R, Yang J, et al. Biomaterials, 2014, 35(36),9731.